Lexeo Therapeutics, Inc. (LXEO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 15.69M USD | Liabilities, Current |
| Cash and equivalents | 92.83M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 118.87M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $15.69M | $92.83M | $118.87M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $14.19M | $71.77M | $121.28M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $16.81M | $63.00M | $118.77M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $17.27M | $41.00M | $81.77M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $31.59M | $35.48M | $97.41M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $30.82M | $28.91M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $22.85M | $35.01M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $26.82M | $157.02M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $18.88M | $174.98M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $21.63M | $195.06M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $17.24M | $121.47M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $23.04M | $35.45M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $14.35M | $77.33M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $94.15M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $135.86M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |